Luqiang Wang

1.0k total citations
26 papers, 508 citations indexed

About

Luqiang Wang is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Luqiang Wang has authored 26 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Luqiang Wang's work include CAR-T cell therapy research (5 papers), Bone health and treatments (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Luqiang Wang is often cited by papers focused on CAR-T cell therapy research (5 papers), Bone health and treatments (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Luqiang Wang collaborates with scholars based in United States, China and United Kingdom. Luqiang Wang's co-authors include Ling Qin, Abhishek Chandra, Wei Tong, Haoruo Jia, Brad S. Kahl, Carmelo Carlo‐Stella, John Radford, Paolo F. Caimi, Robert J. Tower and Xiaoyuan Ma and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Luqiang Wang

25 papers receiving 501 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luqiang Wang United States 12 222 149 148 138 95 26 508
Dagmar Foedinger Austria 13 135 0.6× 283 1.9× 122 0.8× 164 1.2× 159 1.7× 23 573
Raul Perret France 13 200 0.9× 110 0.7× 357 2.4× 111 0.8× 45 0.5× 35 687
Leslie Kurtzberg United States 11 149 0.7× 45 0.3× 437 3.0× 130 0.9× 65 0.7× 14 780
Raffi Manoukian United States 12 183 0.8× 47 0.3× 260 1.8× 111 0.8× 73 0.8× 16 726
Takashi Kazama Japan 12 70 0.3× 102 0.7× 100 0.7× 74 0.5× 70 0.7× 40 472
L. Arganini Italy 12 116 0.5× 211 1.4× 115 0.8× 60 0.4× 36 0.4× 24 569
Raul Mena United States 9 252 1.1× 67 0.4× 107 0.7× 38 0.3× 41 0.4× 18 418
Helene Bjørg Kristensen Denmark 7 174 0.8× 67 0.4× 205 1.4× 50 0.4× 37 0.4× 13 426
Amanda Farrugia Australia 9 659 3.0× 65 0.4× 502 3.4× 157 1.1× 72 0.8× 11 1.0k

Countries citing papers authored by Luqiang Wang

Since Specialization
Citations

This map shows the geographic impact of Luqiang Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luqiang Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luqiang Wang more than expected).

Fields of papers citing papers by Luqiang Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luqiang Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luqiang Wang. The network helps show where Luqiang Wang may publish in the future.

Co-authorship network of co-authors of Luqiang Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Luqiang Wang. A scholar is included among the top collaborators of Luqiang Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luqiang Wang. Luqiang Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kwiatek, Michał, et al.. (2024). ABCL-351 LOTIS-5, an Ongoing, Phase 3 Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL. Clinical Lymphoma Myeloma & Leukemia. 24. S473–S474. 1 indexed citations
3.
Yao, Lutian, Leilei Zhong, Yulong Wei, et al.. (2023). Activin A marks a novel progenitor cell population during fracture healing and reveals a therapeutic strategy. eLife. 12. 10 indexed citations
4.
Kwiatek, Michał, Sebastian Grosicki, Javier López Jiménez, et al.. (2023). ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL. Clinical Lymphoma Myeloma & Leukemia. 23. S439–S440. 4 indexed citations
5.
Wang, Luqiang, Ming Lu, Zhenguo Zhao, et al.. (2023). Risk factors for pulmonary cement embolism after percutaneous vertebroplasty and radiofrequency ablation for spinal metastases. Frontiers in Oncology. 13. 1129658–1129658. 4 indexed citations
6.
Caimi, Paolo F., Weiyun Z. Ai, Juan Pablo Alderuccio, et al.. (2023). Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica. 109(4). 1184–1193. 23 indexed citations
7.
Caimi, Paolo F., Weiyun Z. Ai, Juan Pablo Alderuccio, et al.. (2023). P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. HemaSphere. 7(S3). e402511c–e402511c. 2 indexed citations
8.
Wang, Luqiang, Lutian Yao, Hao Duan, et al.. (2021). Plasminogen Regulates Fracture Repair by Promoting the Functions of Periosteal Mesenchymal Progenitors. Journal of Bone and Mineral Research. 36(11). 2229–2242. 11 indexed citations
9.
Spira, Alexander I., Xiaolei Zhou, Lei Chen, et al.. (2021). Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 22(3). 158–168. 8 indexed citations
10.
Solh, Melhem, Juan Pablo Alderuccio, Brian Hess, et al.. (2021). ABCL-362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis. Clinical Lymphoma Myeloma & Leukemia. 21. S394–S395. 1 indexed citations
11.
Herrera, Alex F., Carmelo Carlo‐Stella, Graham P. Collins, et al.. (2020). Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 136(Supplement 1). 21–23. 14 indexed citations
12.
Hamadani, Mehdi, John Radford, Carmelo Carlo‐Stella, et al.. (2020). Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 137(19). 2634–2645. 122 indexed citations
13.
Tseng, Wei‐Ju, Hongbo Zhao, Yang Liu, et al.. (2020). Short Cyclic Regimen With Parathyroid Hormone (PTH) Results in Prolonged Anabolic Effect Relative to Continuous Treatment Followed by Discontinuation in Ovariectomized Rats. Journal of Bone and Mineral Research. 37(4). 616–628. 6 indexed citations
14.
Yao, Lutian, Elisia D. Tichy, Leilei Zhong, et al.. (2020). Gli1 Defines a Subset of Fibro-adipogenic Progenitors that Promote Skeletal Muscle Regeneration With Less Fat Accumulation. Journal of Bone and Mineral Research. 36(6). 1159–1173. 28 indexed citations
15.
Zhang, Yejia, Zuozhen Tian, Jason W. Ashley, et al.. (2018). Extracellular Matrix and Adhesion Molecule Gene Expression in the Normal and Injured Murine Intervertebral Disc. American Journal of Physical Medicine & Rehabilitation. 98(1). 35–42. 15 indexed citations
16.
Wang, Luqiang, Haoruo Jia, Robert J. Tower, Michael A. Levine, & Ling Qin. (2018). Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats. American Journal of Physiology-Endocrinology and Metabolism. 315(4). E446–E453. 5 indexed citations
17.
Chandra, Abhishek, Luqiang Wang, Tiffany Young, et al.. (2017). Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation‐induced osteoporosis. The FASEB Journal. 32(1). 52–62. 28 indexed citations
18.
Jia, Haoruo, Xiaoyuan Ma, Wei Tong, et al.. (2016). EGFR signaling is critical for maintaining the superficial layer of articular cartilage and preventing osteoarthritis initiation. Proceedings of the National Academy of Sciences. 113(50). 14360–14365. 81 indexed citations
19.
Yang, Qiang, et al.. (2015). Skeletal Lesions in Primary Hyperparathyroidism. The American Journal of the Medical Sciences. 349(4). 321–327. 19 indexed citations
20.
Wang, Luqiang, Kevin J. Keen, & Burt Holland. (2011). Estimation of reliability in a three‐factor model. Statistics in Medicine. 30(11). 1254–1265. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dagmar Foedinger Breakdown of academic impact, for papers by Raul Perret Breakdown of academic impact, for papers by Leslie Kurtzberg Breakdown of academic impact, for papers by Raffi Manoukian Breakdown of academic impact, for papers by Takashi Kazama Breakdown of academic impact, for papers by L. Arganini Breakdown of academic impact, for papers by Raul Mena Breakdown of academic impact, for papers by Helene Bjørg Kristensen Breakdown of academic impact, for papers by Amanda Farrugia
Rankless by CCL
2026